Instil Bio/$TIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Instil Bio
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Ticker
$TIL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
ISIN
US45783C2008
Website
Instil Bio Metrics
BasicAdvanced
$106M
-
-$11.97
-
-
Price and volume
Market cap
$106M
52-week high
$67.36
52-week low
$9.62
Average daily volume
171K
Financial strength
Current ratio
30.331
Quick ratio
14.338
Long term debt to equity
58.156
Total debt to equity
58.156
Interest coverage (TTM)
-6.75%
Management effectiveness
Return on assets (TTM)
-12.59%
Return on equity (TTM)
-44.50%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-2.323
Growth
Earnings per share change (TTM)
-36.85%
3-year earnings per share growth (CAGR)
-25.53%
What the Analysts think about Instil Bio
Analyst ratings (Buy, Hold, Sell) for Instil Bio stock.
Instil Bio Financial Performance
Revenues and expenses
Instil Bio Earnings Performance
Company profitability
Instil Bio News
AllArticlesVideos
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
GlobeNewsWire·8 hours ago
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·1 week ago
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Instil Bio stock?
Instil Bio (TIL) has a market cap of $106M as of May 22, 2025.
What is the P/E ratio for Instil Bio stock?
The price to earnings (P/E) ratio for Instil Bio (TIL) stock is 0 as of May 22, 2025.
Does Instil Bio stock pay dividends?
No, Instil Bio (TIL) stock does not pay dividends to its shareholders as of May 22, 2025.
When is the next Instil Bio dividend payment date?
Instil Bio (TIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Instil Bio?
Instil Bio (TIL) does not currently have a Beta indicator.